Literature DB >> 12050358

Human monocytic cell lines transformed in vitro by Epstein-Barr virus display a type II latency and LMP-1-dependent proliferation.

Eric Masy1, Eric Adriaenssens, Claire Montpellier, Pascale Crépieux, Alexandra Mougel, Brigitte Quatannens, Gautier Goormachtigh, Nathalie Faumont, Fabienne Meggetto, Claude Auriault, Hervé Groux, Jean Coll.   

Abstract

Epstein-Barr virus (EBV) classically infects and transforms B lymphocytes in vitro, yielding lymphoblastoid cell lines (LCLs). In contrast to other herpesviruses, EBV is not described as an infectious agent for monocytes. However, recent papers described in vitro infection of monocytes leading to abortive or transient viral expression. In the present study, we report the characterization of E1, a monocytic cell line infected and transformed by EBV. This cell line was derived from an LCL by a drastic electroporation and selection of neomycin-resistant cells, unfavorable to B-cell outgrowth. E1 expressed surface molecules of monocytic lineage (CD14, major histocompatibility complex class II, and CD80) and the c-fms gene, a highly specific marker for the monocytic lineage. This cell line is able to phagocytose and secrete proinflammatory monokines tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-8. E1 cells are tumorigenic after injection in nude mice, and a monocytic cell line obtained from one of these tumors (TE1) displayed immunophenotype and functional properties similar to those of E1. We detected the presence of the EBV genome in both cell lines, as well as expression of the EBNA-1 and LMP-1, but not EBNA-2, viral genes, characteristic of a type II latency. LMP-1 influences the phenotype of these monocytic cell lines, as demonstrated by down-regulation of cell proliferation and membrane intercellular adhesion molecule 1 expression due to an LMP-1 antisense strategy. This is the first description of a latently infected human monocytic cell line and the first direct demonstration of an instrumental role for LMP-1 in the proliferation of EBV-transformed cell lines expressing a type II latency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050358      PMCID: PMC136267          DOI: 10.1128/jvi.76.13.6460-6472.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Expression of latent and replicative-infection genes of Epstein-Barr virus in macrophage.

Authors:  M Shimakage; M Kimura; S Yanoma; M Ibe; S Yokota; G Tsujino; T Kozuka; T Dezawa; S Tamura; A Ohshima; M Yutsudo; A Hakura
Journal:  Arch Virol       Date:  1999       Impact factor: 2.574

2.  Antisense oligodeoxynucleotides to latent membrane protein 1 induce growth inhibition, apoptosis and Bcl-2 suppression in Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cells, but not in EBV-positive natural killer cell lymphoma cells.

Authors:  T Noguchi; K Ikeda; K Yamamoto; I Yoshida; A Ashiba; J Tsuchiyama; K Shinagawa; T Yoshino; M Takata; M Harada
Journal:  Br J Haematol       Date:  2001-07       Impact factor: 6.998

3.  Expression of c-Myc in response to colony-stimulating factor-1 requires mitogen-activated protein kinase kinase-1.

Authors:  M Cheng; D Wang; M F Roussel
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

4.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.

Authors:  D Wang; D Liebowitz; E Kieff
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

5.  Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome.

Authors:  H Kawaguchi; T Miyashita; H Herbst; G Niedobitek; M Asada; M Tsuchida; R Hanada; A Kinoshita; M Sakurai; N Kobayashi
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

6.  Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression.

Authors:  O Devergne; E D Cahir McFarland; G Mosialos; K M Izumi; C F Ware; E Kieff
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

7.  Homologous T and B cells immortalized in vitro by the Epstein-Barr virus exhibit differential genetical and functional features.

Authors:  C Montpellier; P Crepieux; B Quatannens; B Delobel; M Croquette; D Stehelin; C Auriault; H Groux; J Coll
Journal:  Int J Oncol       Date:  1997-07       Impact factor: 5.650

8.  Inflammatory cytokines in virus-associated hemophagocytic syndrome. Interferon-gamma as a sensitive indicator of disease activity.

Authors:  S Ohga; A Matsuzaki; M Nishizaki; T Nagashima; T Kai; M Suda; K Ueda
Journal:  Am J Pediatr Hematol Oncol       Date:  1993-08

9.  Fatal Epstein-Barr virus-associated hemophagocytic syndrome.

Authors:  H Kikuta; Y Sakiyama; S Matsumoto; T Oh-Ishi; T Nakano; T Nagashima; T Oka; T Hironaka; K Hirai
Journal:  Blood       Date:  1993-12-01       Impact factor: 22.113

10.  Epstein-Barr virus-associated hemophagocytic syndrome.

Authors:  H Kikuta
Journal:  Leuk Lymphoma       Date:  1995-02
View more
  13 in total

1.  Epstein-Barr virus (EBV)-infected monocytes facilitate dissemination of EBV within the oral mucosal epithelium.

Authors:  Sharof Tugizov; Rossana Herrera; Piri Veluppillai; John Greenspan; Deborah Greenspan; Joel M Palefsky
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

2.  17-Beta estradiol enhances prostaglandin E2 production in human U937-derived macrophages.

Authors:  Biao Lu; Yan J Jiang; Patrick C Choy
Journal:  Mol Cell Biochem       Date:  2004-07       Impact factor: 3.396

3.  Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH.

Authors:  Sara Calattini; Irini Sereti; Philip Scheinberg; Hiroshi Kimura; Richard W Childs; Jeffrey I Cohen
Journal:  Blood       Date:  2010-08-10       Impact factor: 22.113

4.  Inhibition of latent membrane protein 1 impairs the growth and tumorigenesis of latency II Epstein-Barr virus-transformed T cells.

Authors:  Papa Alioune Ndour; Guillaume Brocqueville; Tan-Sothéa Ouk; Gautier Goormachtigh; Olivier Morales; Alexandra Mougel; Julie Bertout; Oleg Melnyk; Véronique Fafeur; Jean Feuillard; Jean Coll; Eric Adriaenssens
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

5.  Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways.

Authors:  Gautier Goormachtigh; Tan-Sothéa Ouk; Alexandra Mougel; Denis Tranchand-Bunel; Eric Masy; Christophe Le Clorennec; Jean Feuillard; Georg W Bornkamm; Claude Auriault; Evelyne Manet; Véronique Fafeur; Eric Adriaenssens; Jean Coll
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

6.  A replication-defective gammaherpesvirus efficiently establishes long-term latency in macrophages but not in B cells in vivo.

Authors:  Haiyan Li; Kazufumi Ikuta; John W Sixbey; Scott A Tibbetts
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

7.  The Epstein-Barr virus BMRF-2 protein facilitates virus attachment to oral epithelial cells.

Authors:  Jianqiao Xiao; Joel M Palefsky; Rossana Herrera; Jennifer Berline; Sharof M Tugizov
Journal:  Virology       Date:  2007-10-22       Impact factor: 3.616

8.  Induction of therapeutic antibodies by vaccination against external loops of tumor-associated viral latent membrane protein.

Authors:  Catherine Delbende; Claudie Verwaerde; Alexandra Mougel; Denis Tranchand Bunel
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

9.  Sequencing of DC-SIGN promoter indicates an association between promoter variation and risk of nasopharyngeal carcinoma in cantonese.

Authors:  Ya-Fei Xu; Wan-Li Liu; Ju-Qin Dong; Wen-Sheng Liu; Qi-Sheng Feng; Li-Zhen Chen; Yi-Xin Zeng; Mu-Sheng Zeng; Wei-Hua Jia
Journal:  BMC Med Genet       Date:  2010-11-11       Impact factor: 2.103

10.  LMP1-induced cell death may contribute to the emergency of its oncogenic property.

Authors:  Guillaume Brocqueville; Papa Alioune Ndour; Tan-Sothéa Ouk; Arnaud Le Goff; Caroline De Witte; Alexandra Mougel; Jean Coll; Véronique Fafeur; Xuefen Le Bourhis; Eric Adriaenssens
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.